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Abstract
Background: Multiple sclerosis (MS) risk, over 10-fold higher in Western than in Asian countries,
is associated with elevated IgG antibody titers against Epstein-Barr viral capcid antigen (anti-EBVCA
IgG titers). Given the 84% homology of the open reading frame BCRF1 of Epstein-Barr virus (EBV)
to human interleukin 10 (hIL-10) and the remarkable Caucasian-vs.-Asian population differences in
hIL-10 gene promoter polymorphisms, this strong association of MS risk with anti-EB-VCA IgG
titers may be explained by the genetic variations in the hIL-10 gene.
Methods: We evaluated anti-EB-VCA IgG titers in association with a single nucleotide
polymorphism (SNP) in the promoter of hIL-10 at position -819 (hIL-10 T-819C) in a cross-
sectional survey of 241 Japanese. Anti-EB-VCA IgG titer and its elevation (≥ 1:160) were evaluated,
stratified by sex and hIL-10 T-819C genotype.
Results: The cytosine-allele frequencies at hIL-10 T-819C were 32.9% in women and 30.9% in
men. These are consistent with the published reports of Japanese and Chinese, but substantially
lower than those of Caucasians (> 70%). In women, the proportion with elevated anti-EB-VCA IgG
titers (≥ 1:160) increased appreciably from 53.7% in the T/T genotype group to 66.7% in the T/C
group and to 83.3% in the C/C group (P-trend = 0.037). The titers did not differ by the hIL-10 T-
819C genotype in men.
Conclusion: Anti-EB-VCA IgG titers may increase with the number of cytosine alleles at hIL-10
T-819C in women. This observed gender specific association in Japanese warrants further
investigation, especially in Western populations with high MS risk.
Background
Human interleukin 10 (hIL-10) is a pleiotropic cytokine
with multifaceted functions in the regulation of immune
and inflammatory responses [1]. It limits cell-mediated
immune responses by inhibiting the activation of macro-
phages, monocytes, and dendritic cells. In B cells, hIL-10
Published: 4 March 2008
Journal of Autoimmune Diseases 2008, 5:2 doi:10.1186/1740-2557-5-2
Received: 6 February 2008
Accepted: 4 March 2008
This article is available from: http://www.jautoimdis.com/content/5/1/2
© 2008 Yasui et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
Journal of Autoimmune Diseases 2008, 5:2 http://www.jautoimdis.com/content/5/1/2promotes cell proliferation and differentiation, and also
plays some anti-apoptotic function. These biological
activities of hIL-10 are advantageous for viruses that infect
and persist in B cells. Indeed, Epstein-Barr virus (EBV), as
well as some other members of the herpes virus family,
appears to use mimicry of hIL-10 functions as part of their
survival strategies in the host. Specifically, an open read-
ing frame of EBV, BCRF1, shows a strikingly high degree
of sequence homology with hIL-10 (84% homology in
amino acid sequence) and viral IL-10 shares many of hIL-
10's biological activities [1]. Based on these observations,
we hypothesize that genetic variations in the host's hIL-10
gene may modulate the host-organism interaction with
this ubiquitous virus encoding an hIL-10 mimic.
This hypothesis is of particular interest as both the risk of
multiple sclerosis (MS) and the cytosine-allele frequency
at position -819 in the promoter region of hIL-10 (hIL-10
T-819C) are considerably higher in Western, compared to
Chinese and Japanese populations (MS prevalence of < 5
per 100,000 in China and Japan [2] vs. > 50 per 100,000
in the US [3] and the cytosine-allele frequency at hIL-10 T-
819C of 28.8–32.7% in Chinese and Japanese [4-7] vs.
71.8–83.6% in Caucasians [7-12]). Furthermore, there is
a strong positive association between MS risk and elevated
pre-diagnosis IgG antibody titers against Epstein-Barr viral
capsid antigen (anti-EBVCA IgG titers) [13-21] although
an inverse association has been observed in one prospec-
tive study [22].
To test the hypothesis, anti-EB-VCA IgG titers were meas-
ured as an indicator of the host-virus interaction, and
compared across the genotypes of the hIL-10 promoter
single nucleotide polymorphism (SNP) at hIL-10 T-819C.
Methods
Study population
A cross-sectional survey was conducted including 241 Jap-
anese outpatients, 123 females and 118 males, aged
39–69, without any history of cancer, who underwent
physical examination and gastroscopy at the Aichi Cancer
Center Hospital between March and December 1999.
Patients with autoimmune diseases were excluded. A writ-
ten informed consent for providing peripheral blood sam-
ple and its analysis for DNA polymorphisms was obtained
from each participant.
IL-10 polymorphism assay and EBV antibody assay
DNA was extracted from buffy coat using a QIAamp blood
mini kit (Qiagen, Valencia, CA) and the hIL-10 promoter
SNP at position -819 was characterized by the polymerase
chain reaction with confronting two-pair primers (PCR-
CTPP), which does not require restriction enzyme diges-
tion, developed by our laboratory [23].
Anti-EB-VCA IgG titers were measured using plasma sam-
ples by indirect immunofluorescence [24] at a commer-
cial laboratory (Mitsubishi Chemical BCL, Tokyo, Japan).
The titer was defined by the maximum dilution with defi-
nitely visible fluorescence. Titers at or above the median
level (≥ 1:160) were considered to be "elevated." In a sep-
arate study with 600 samples, we tested the laboratory's
assay reliability by including 30 blinded identical quality-
control samples in the 600 samples. The laboratory
showed an excellent reliability returning an identical anti-
EB-VCA IgG titer for 27 of the 30 samples and the one-
dilution lower titer for the remaining 3 samples.
Statistical analysis
Geometric mean and standard deviation of anti-EB-VCA
IgG titers were calculated for each hIL-10 T-819C geno-
type and stratified by sex. Elevation of anti-EB-VCA IgG
titers (≥ 1:160) in relation to the hIL-10 T-819C genotypes
was examined by unconditional logistic regression [25]
adjusting for age and stratified by sex. The observed geno-
type groups were T/T, T/C, and C/C. The trend in the pro-
portion of elevated titers across the three genotypes,
ordered by the number of cytosine alleles, was examined
by Armitage-Cochran Trend Test [26], adjusting for age.
All significance tests were two sided.
Results
Table 1 shows the geometric mean and standard deviation
of anti-EB-VCA IgG titers by the hIL-10 T-819C genotype,
stratified by sex. The geometric mean titer increased
monotonically with the number of cytosine alleles among
Table 1: Geometric mean and standard deviation of IgG antibody titers against Epstein-Barr viral capsid antigen (anti-EB-VCA IgG 
titer) by IL-10 T-819C genotype, stratified by sex
IL-10 T-819C genotype Women Men
Total number (%) Geometric mean anti-EB-VCA IgG titer 
(×/÷ Geometric standard deviation)
Total number (%) Geometric mean anti-EB-VCA IgG titer 
(×/÷ Geometric standard deviation)
T/T 54 (43.9) 1:127 (×/÷ 2.4) 56 (47.5) 1:122 (×/÷ 2.0)
T/C 57 (46.3) 1:152 (×/÷ 2.1) 51 (43.2) 1:140 (×/÷ 2.0)
C/C 12 (9.8) 1:190 (×/÷ 2.1) 11 (9.3) 1:124 (×/÷ 2.7)Page 2 of 5
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portion with elevated anti-EB-VCA IgG titers increased
from 53.7% in the T/T group to 66.7% in the T/C group
and 83.3% in the C/C groups (P-trend = 0.037) (Table 2).
This was not seen among the 118 men (P-trend = 0.84).
The difference of the trend between the sexes was margin-
ally statistically significant (P = 0.097).
Discussion
In this study, we found a monotonic increase in anti-EB-
VCA IgG titers with the number of cytosine alleles at the
hIL-10 T-819C locus in Japanese women, however not in
men. Considering the higher prevalence of both MS [2,3]
and the specific SNP in the promoter of hIL-10T-819C [4-
12] in Western populations compared to Asian popula-
tions, and the strong positive association of MS risk with
anti-EB-VCA IgG titers [13-21], our finding has an impor-
tant implication on MS susceptibility. Specifically, it sug-
gests a genetic predisposition to MS in the hIL-10 gene
promoter, relevant only in women.
Such female-specific MS-risk-elevating function is consist-
ent with the notion that gonadal steroids regulate the gen-
der dimorphism in MS and other autoimmune diseases
[27]. Indeed, in the mouse model of MS, experimental
autoimmune encephalomyelitis in SJL mice, disease
severity is increased by castration in male mice [28] and
decreased by testosterone implantation in females [29].
The immunomodulatory effects of gonadal steroids, espe-
cially, testosterone, may underlie the female-specific asso-
ciation of anti-EB-VCA IgG titers with hIL-10 T-819C
observed here.
Studies that have investigated human MS risk in relation
to polymorphisms in hIL-10 have found no association
[30-37]. These studies, however, investigated Western
high-risk populations where the cytosine-allele frequen-
cies at hIL-10 T-819C are very high (> 70%). They did not
investigate, with a few exceptions, the polymorphism at
hIL-10 T-819C whose genotype distributions are mark-
edly different between the high- and low-risk populations
of MS, and did not stratify the association analysis by gen-
der. It is also a possibility that the T-819C polymorphism
and the associated IL-10 levels may modulate the immune
response and MS risk, given some observed correlation
between the promoter polymorphism and the IL-10 levels
in in vitro/in vivo [38]. It would be of interest to evaluate
MS risk in relation to the hIL-10 T-819C genotype: (1) in
populations where thymine-allele frequencies at hIL-10 T-
819C are sufficiently high (e.g., Chinese and Japanese);
and perhaps more importantly, (2) in any population
stratified by gender.
Our findings are, however, consistent with a recent study
of a small patient cohort showing a statistically significant
increase in CC genotype of hIL-10 SNPs at -819 and -592
loci in MS patients [39]. The hIL-10 promoter polymor-
phism at the -819 locus is often analyzed along with the
hIL-10 promoter polymorphisms at the -1082 and -592,
which is justified by their strong linkage disequilibrium,
in addition to the three main haplotypes (GCC, ACC,
ATA, and very rarely GTA, at the -1082, -819, and -592
locus) found to segregate in most populations. Because
we did not study the -1082 locus, we were unable to sep-
arate the GCC and ACC haplotypes. However, G alleles at
the -1082 locus are very rare (G-allele frequency < 4%) in
Japanese and Chinese populations [4-7].
Conclusion
Given the high homology of viral IL-10 to hIL-10, the
established association of MS with elevated anti-EB-VCA
IgG titers, and the public health/personal burden of MS,
our finding of female-specific increase in anti-EB-VCA IgG
titers with the number of cytosine alleles at hIL-10 T-819C
warrants further investigation. Such investigations may
lead to an explanation of high MS risk in Western popula-
tions, where the MS disease burden is more than 10 times
higher than that in Japan and China, and the cytosine-
allele frequencies at hIL-10 T-819C are at least twice as
high (> 70% vs. 30%) as those in Chinese and Japanese
populations.
Table 2: Elevation of IgG antibody titers (≥ 1:160) against Epstein-Barr viral capsid antigen (anti-EB-VCA titer) by IL-10 T-819C 
genotype, stratified by sex+
IL-10 T-819C Genotype Women Men
Number with anti-EB-VCA 
IgG titer ≥ 1:160/Total (%)
Odds ratio of anti-EB-VCA 
IgG titer ≥ 1:160 (95% CI)
Number with anti-EB-VCA 
IgG titer ≥ 1:160/Total (%)
Odds ratio of anti-EB-VCA 
IgG titer ≥ 1:160 (95% CI)
T/T 29/54 (53.7) 1.00 (Reference) 32/56 (57.1) 1.00 (Reference)
T/C 38/57 (66.7) 1.72 (0.80–3.75) 32/51 (62.7) 1.26 (0.58–2.76)
C/C 10/12 (83.3) 4.31 (1.01–29.79) 5/11 (45.5) 0.63 (0.16–2.31)
P-trend* = 0.037 P-trend* = 0.84
*Armitage-Cochran Trend Test, adjusted for age
+Trend difference between sexes: P = 0.097Page 3 of 5
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